Teva Pharmaceutical Industries Stock Price, News & Analysis (NYSE:TEVA)

$21.02 0.32 (1.55 %)
(As of 01/22/2018 04:00 PM ET)
Previous Close$21.02
Today's Range$20.15 - $21.39
52-Week Range$10.85 - $37.94
Volume20.76 million shs
Average Volume27.11 million shs
Market Capitalization$20.96 billion
P/E Ratio-3.58
Dividend Yield4.04%
Beta0.54

About Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries logoTeva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams. Its specialty medicines business focuses on delivering a range of solutions to patients and providers through medicines, devices and services in various regions and markets around the world. Its specialty medicines business includes its core therapeutic areas of central nervous system (CNS) and respiratory medicines with a focus on asthma and chronic obstructive pulmonary disease. It also has specialty products in oncology, women's health and selected other areas.

Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolNYSE:TEVA
CUSIPN/A
Phone+972-3-9267267

Debt

Debt-to-Equity Ratio1.20%
Current Ratio0.96%
Quick Ratio0.66%

Price-To-Earnings

Trailing P/E Ratio-3.5809199318569
Forward P/E Ratio5.62
P/E Growth1.48

Sales & Book Value

Annual Sales$21.90 billion
Price / Sales0.98
Cash Flow$6.69 per share
Price / Cash3.14
Book Value$30.91 per share
Price / Book0.68

Profitability

Trailing EPS($5.87)
Net Income$329 million
Net Margins-24.35%
Return on Equity15.70%
Return on Assets5.12%

Miscellaneous

Employees56,960
Outstanding Shares1,016,000,000

Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

How often does Teva Pharmaceutical Industries pay dividends? What is the dividend yield for Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries declared a quarterly dividend on Thursday, November 2nd. Stockholders of record on Tuesday, November 28th will be paid a dividend of $0.085 per share on Tuesday, December 12th. This represents a $0.34 dividend on an annualized basis and a dividend yield of 1.62%. The ex-dividend date of this dividend is Monday, November 27th. View Teva Pharmaceutical Industries' Dividend History.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) released its quarterly earnings data on Thursday, November, 2nd. The company reported $0.95 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.03 by $0.08. Teva Pharmaceutical Industries had a positive return on equity of 15.70% and a negative net margin of 24.35%. View Teva Pharmaceutical Industries' Earnings History.

When will Teva Pharmaceutical Industries make its next earnings announcement?

Teva Pharmaceutical Industries is scheduled to release their next quarterly earnings announcement on Thursday, February, 8th 2018. View Earnings Estimates for Teva Pharmaceutical Industries.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its fourth quarter earnings guidance on Thursday, November, 2nd. The company provided earnings per share (EPS) guidance of $0.70-0.80 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.06. The company issued revenue guidance of $5.3-5.4 billion, compared to the consensus revenue estimate of $5.68 billion.

Where is Teva Pharmaceutical Industries' stock going? Where will Teva Pharmaceutical Industries' stock price be in 2018?

27 brokerages have issued 12-month price objectives for Teva Pharmaceutical Industries' stock. Their predictions range from $11.00 to $43.00. On average, they anticipate Teva Pharmaceutical Industries' stock price to reach $21.32 in the next year. View Analyst Ratings for Teva Pharmaceutical Industries.

What are Wall Street analysts saying about Teva Pharmaceutical Industries stock?

Here are some recent quotes from research analysts about Teva Pharmaceutical Industries stock:

  • 1. According to Zacks Investment Research, "Teva is facing significant challenges in the form of generic competition for Copaxone, new competition for branded products, pricing erosion in the U.S. generics business, lower-than-expected contribution from new generic launches and a massive debt load. Also, Teva’s shares have underperformed the generic industry in the past one year. Mylan’s earlier-than-expected launch of the first generic version of the 40-mg strength of Copaxone was a major setback for Teva. Though Teva has divested some non-core assets to cut its significant debt load and aims to cut its global workforce by more than 25% over the next two years, a clear path to growth is not visible. Estimates have gone up ahead of the company’s Q4 earnings release due to expected cost savings from the restructuring plan. Teva has a negative record of earnings surprises. " (1/12/2018)
  • 2. Cantor Fitzgerald analysts commented, "This morning Teva announced more details of its new strategic plan under CEO Kare Schultz, including the layoff of 14,000 people. This is meaningfully above the Street’s estimate of 10,000 jobs." (12/14/2017)
  • 3. Maxim Group analysts commented, "Shares of TEVA are under pressure in the wake of the FDA’s approval of Mylan’s ANDA for generic copaxone 3x/week & 20 mg/ml QD injection. Teva has a press release estimating the impact of the two launches to its 4Q earnings of at least $0.25. Our estimates are under review but our Hold remaining remains in-effect. We had anticipated generic copaxone (3x) but not until 2018." (10/4/2017)
  • 4. Jefferies Group LLC analysts commented, "MDCO announced early stoppage of the Ph 3 TANGO-2 trial for Vabomere (Carbavance) based on an interim analysis which showed a superior benefit-risk compared to best available therapy in serious infections due to CRE. We are impressed by DSMB stoppage of a trial with less than half of patients enrolled (72 out of the 150 target) suggesting a dramatic clinical benefit vs. standard of care. We believe today’s news provides a favorable setup for the August 21 (our estimate) PDUFA for Vabomere in cUTI. We continue to see Vabomere as a potential source of optionality for MDCO should management decide to launch this important new antibiotic on their own or in conjunction with a partner." (7/25/2017)

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a increase in short interest in the month of December. As of December 29th, there was short interest totalling 87,650,494 shares, an increase of 8.4% from the December 15th total of 80,866,638 shares. Based on an average daily volume of 19,333,494 shares, the short-interest ratio is presently 4.5 days.

Who are some of Teva Pharmaceutical Industries' key competitors?

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the folowing people:

  • Sol J. Barer Ph.D., Chairman of the Board (Age 69)
  • Kaare Schultz, President, Chief Executive Officer (Age 56)
  • Michael McClellan, Chief Financial Officer, Executive Vice President
  • Iris Beck-Codner, Executive Vice President - Global Brand & Communications (Age 52)
  • Richard Daniell, Executive Vice President - European Commercial
  • Carlo de Notaristefani, Executive Vice President - Global Operations (Age 59)
  • Sven Dethlefs Ph.D., Executive Vice President - Global Marketing & Portfolio
  • Hafrun Fridriksdottir, Executive Vice President - Global R&D (Age 55)
  • Gianfranco Nazzi, Executive Vice President - Growth Markets Commercial
  • Brendan O'Grady, Executive Vice President - North America Commercial

Who owns Teva Pharmaceutical Industries stock?

Teva Pharmaceutical Industries' stock is owned by many different of institutional and retail investors. Top institutional shareholders include ALLERGAN PLC (6.80%), ALLERGAN PLC (6.80%), First Manhattan Co. (0.13%), National Pension Service (0.10%), Bank of Montreal Can (0.05%) and Schwab Charles Investment Management Inc. (0.03%). View Institutional Ownership Trends for Teva Pharmaceutical Industries.

Who sold Teva Pharmaceutical Industries stock? Who is selling Teva Pharmaceutical Industries stock?

Teva Pharmaceutical Industries' stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Kempner Capital Management Inc., Bank of Montreal Can, Gofen & Glossberg LLC IL, Private Asset Management Inc., Bridge Creek Capital Management LLC, Lockheed Martin Investment Management Co. and Macnealy Hoover Investment Management Inc.. View Insider Buying and Selling for Teva Pharmaceutical Industries.

Who bought Teva Pharmaceutical Industries stock? Who is buying Teva Pharmaceutical Industries stock?

Teva Pharmaceutical Industries' stock was acquired by a variety of institutional investors in the last quarter, including National Pension Service, Pennsylvania Trust Co, Greylin Investment Mangement Inc., Schwab Charles Investment Management Inc. and Cornerstone Investment Partners LLC. View Insider Buying and Selling for Teva Pharmaceutical Industries.

How do I buy Teva Pharmaceutical Industries stock?

Shares of Teva Pharmaceutical Industries can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Teva Pharmaceutical Industries' stock price today?

One share of Teva Pharmaceutical Industries stock can currently be purchased for approximately $21.02.

How big of a company is Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has a market capitalization of $20.96 billion and generates $21.90 billion in revenue each year. The company earns $329 million in net income (profit) each year or ($5.87) on an earnings per share basis. Teva Pharmaceutical Industries employs 56,960 workers across the globe.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 Basel St., P.O. Box 3190, PETAH TIKVA, 49131, Israel. The company can be reached via phone at +972-3-9267267 or via email at [email protected]


MarketBeat Community Rating for Teva Pharmaceutical Industries (TEVA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  923 (Vote Outperform)
Underperform Votes:  770 (Vote Underperform)
Total Votes:  1,693
MarketBeat's community ratings are surveys of what our community members think about Teva Pharmaceutical Industries and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Teva Pharmaceutical Industries (NYSE:TEVA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.072.122.042.58
Ratings Breakdown: 5 Sell Rating(s)
15 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
17 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
15 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
10 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.32$20.14$25.95$42.22
Price Target Upside: 2.98% upside8.20% upside74.18% upside30.04% upside

Teva Pharmaceutical Industries (NYSE:TEVA) Consensus Price Target History

Price Target History for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/22/2018Maxim GroupReiterated RatingHoldLowView Rating Details
1/22/2018Wells Fargo & CoReiterated RatingSellLowView Rating Details
1/18/2018BTIG ResearchDowngradeBuy -> Neutral$24.00LowView Rating Details
1/11/2018Goldman Sachs GroupBoost Price TargetBuy$20.00 -> $25.00HighView Rating Details
1/9/2018MizuhoUpgradeNeutral -> Buy$19.12 -> $23.00N/AView Rating Details
1/4/2018CitigroupUpgradeNeutral -> Buy$24.00LowView Rating Details
1/3/2018Cantor FitzgeraldSet Price TargetHold$18.00MediumView Rating Details
1/2/2018Leerink SwannInitiated CoverageUnderperform -> Underperform$15.00MediumView Rating Details
12/15/2017Royal Bank of CanadaSet Price TargetSell$13.00LowView Rating Details
12/15/2017Deutsche BankSet Price TargetHold$20.00MediumView Rating Details
12/15/2017Credit Suisse GroupUpgradeUnderperform -> Neutral$8.00 -> $20.00MediumView Rating Details
12/15/2017Morgan StanleyUpgradeUnderweight -> Equal Weight$18.00MediumView Rating Details
12/14/2017Piper Jaffray CompaniesSet Price TargetHold$16.00HighView Rating Details
12/14/2017OppenheimerReiterated RatingHoldHighView Rating Details
12/12/2017GuggenheimInitiated CoverageNeutral -> Neutral$16.00HighView Rating Details
11/13/2017JPMorgan Chase & Co.DowngradeNeutral -> Underweight$11.48 -> $11.00N/AView Rating Details
11/6/2017Susquehanna BancsharesLower Price TargetPositive -> Positive$20.00 -> $14.00N/AView Rating Details
10/25/2017Evercore ISISet Price TargetBuy$38.00N/AView Rating Details
10/20/2017BarclaysSet Price TargetHold$21.00 -> $19.00N/AView Rating Details
10/4/2017CowenReiterated RatingMarket Perform$30.00 -> $18.00N/AView Rating Details
9/21/2017Sanford C. BernsteinLower Price TargetMkt Perform -> Market Perform$28.00 -> $20.00LowView Rating Details
9/13/2017GabelliReiterated RatingBuyLowView Rating Details
9/12/2017Jefferies GroupLower Price TargetHold$21.00 -> $18.50HighView Rating Details
9/6/2017JMP SecuritiesBoost Price TargetUnderperform$13.00 -> $14.00LowView Rating Details
8/3/2017CIBCReiterated RatingOutperform -> Market PerformHighView Rating Details
2/28/2017ArgusDowngradeBuy -> Hold$59.35 -> $31.90N/AView Rating Details
1/31/2017Bank of AmericaUpgradeNeutral -> BuyN/AView Rating Details
9/29/2016OTR GlobalInitiated CoveragePositiveN/AView Rating Details
4/19/2016Canaccord GenuityReiterated RatingBuyN/AView Rating Details
3/2/2016NomuraReiterated RatingNeutral$73.00N/AView Rating Details
(Data available from 1/22/2016 forward)

Earnings

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings History and Estimates Chart

Earnings by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE TEVA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/8/2018$0.75N/AView Earnings Details
11/2/2017Q3 2017$1.03$0.95ViewN/AView Earnings Details
8/3/20176/30/2017$1.06$0.99$5.72 billion$5.69 billionViewListenView Earnings Details
5/11/2017Q1 17$1.06$1.06$5.69 billion$5.63 billionViewN/AView Earnings Details
2/13/2017Q416$1.36$1.38$6.26 billion$6.25 billionViewN/AView Earnings Details
11/15/2016Q316$1.29$1.31$5.71 billion$5.56 billionViewN/AView Earnings Details
8/4/2016Q216$1.20$1.25$4.86 billion$5.00 billionViewN/AView Earnings Details
5/9/2016Q116$1.17$1.20$4.78 billion$4.81 billionViewN/AView Earnings Details
2/11/2016Q415$1.29$1.28$4.83 billion$4.88 billionViewListenView Earnings Details
10/29/2015Q315$1.28$1.35$4.75 billion$4.80 billionViewListenView Earnings Details
7/30/2015Q215$1.31$1.43$4.90 billion$4.97 billionViewListenView Earnings Details
4/30/2015Q115$1.26$1.36$4.84 billion$5.00 billionViewN/AView Earnings Details
2/5/2015Q414$1.31$1.31$5.17 billion$5.17 billionViewN/AView Earnings Details
10/30/2014Q314$1.23$1.32$5.09 billion$5.06 billionViewN/AView Earnings Details
7/31/2014Q214$1.21$1.23$5.08 billion$5.00 billionViewN/AView Earnings Details
5/1/2014Q114$1.22$1.22$5.11 million$5.00 billionViewN/AView Earnings Details
2/6/2014Q413$1.26$1.42$5.19 billion$5.40 billionViewN/AView Earnings Details
10/31/2013Q313$1.26$1.27$5.00 billion$5.06 billionViewN/AView Earnings Details
8/1/2013Q213$1.20$1.20$4.94 billion$4.90 billionViewN/AView Earnings Details
5/2/2013Q113$1.10$1.12$4.85 billion$4.90 billionViewN/AView Earnings Details
2/7/2013Q412$1.33$1.32$5.26 billion$5.20 billionViewN/AView Earnings Details
11/1/2012Q312$1.25$1.28$5.08 billion$5.00 billionViewN/AView Earnings Details
8/2/2012$1.28$1.28ViewN/AView Earnings Details
5/9/2012$1.44$1.47ViewN/AView Earnings Details
2/15/2012$1.58$1.59ViewN/AView Earnings Details
11/2/2011$1.22$1.25ViewN/AView Earnings Details
7/27/2011$1.08$1.10ViewN/AView Earnings Details
5/11/2011$1.03$1.04ViewN/AView Earnings Details
2/8/2011$1.28$1.25ViewN/AView Earnings Details
11/2/2010Q3 2010$1.27$1.30ViewN/AView Earnings Details
7/26/2010Q2 2010$1.04$1.08ViewN/AView Earnings Details
5/4/2010Q1 2010$0.89$0.92ViewN/AView Earnings Details
2/16/2010Q4 2009$0.95$0.94ViewN/AView Earnings Details
11/3/2009Q3 2009$0.88$0.89ViewN/AView Earnings Details
7/28/2009Q2 2009$0.80$0.83ViewN/AView Earnings Details
5/5/2009Q1 2009$0.67$0.72ViewN/AView Earnings Details
2/17/2009Q4 2008$0.73$0.76ViewN/AView Earnings Details
11/6/2008Q3 2008$0.69$0.72ViewN/AView Earnings Details
7/29/2008Q2 2008$0.64$0.65ViewN/AView Earnings Details
5/6/2008Q1 2008$0.63$0.64ViewN/AView Earnings Details
2/12/2008Q4 2007$0.66$0.69ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Teva Pharmaceutical Industries (NYSE:TEVA) Earnings Estimates

Current Year EPS Consensus Estimate: $3.74 EPS
Next Year EPS Consensus Estimate: $2.8 EPS

Dividends

Teva Pharmaceutical Industries (NYSE:TEVA) Dividend Information

Most Recent Dividend:12/12/2017
Annual Dividend:$0.72
Dividend Yield:3.43%
Dividend Growth:-14.40% (3 Year Average)
Payout Ratio:-12.27% (Trailing 12 Months of Earnings)
19.25% (Based on This Year's Estimates)
25.71% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
11/2/2017quarterly$0.092.74%11/27/201711/28/201712/12/2017
8/7/2017quarterly$0.091.83%8/25/20178/29/20179/14/2017
5/11/2017quarterly$0.344.28%6/1/20176/5/20176/22/2017
2/13/2017quarterly$0.343.7%2/28/20173/2/20173/20/2017
11/15/2016quarterly$0.3412/1/201612/5/201612/20/2016
8/4/2016quarterly$0.348/18/20168/22/20169/8/2016
5/9/2016quarterly$0.345/20/20165/24/20166/7/2016
2/16/2016Quarterly$0.292/25/20162/29/20163/14/2016
10/29/2015quarterly$0.3411/13/201511/17/201512/3/2015
7/30/2015quarterly$0.348/18/20158/20/20159/3/2015
5/5/2015special$0.342.25%5/15/20155/19/20156/4/2015
2/5/2015quarterly$0.342.36%2/17/20152/19/20153/3/2015
10/31/2014special$0.322.43%11/13/201411/17/201412/2/2014
8/1/2014quarterly$0.352.61%8/19/20148/21/20149/4/2014
5/2/2014quarterly$0.352.77%5/16/20145/20/20146/2/2014
2/4/2014$0.342/20/20142/24/20143/10/2014
11/1/2013quarterly$0.333.51%11/18/201311/20/201312/2/2013
8/5/2013quarterly$0.323.34%8/16/20138/20/20139/3/2013
8/1/2013quarterly$0.328/20/20139/2/2013
5/6/2013special$0.323.28%5/16/20135/20/20136/3/2013
2/8/2013quarterly$0.313.21%2/19/20132/21/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Teva Pharmaceutical Industries (NYSE TEVA)

No insider trades for this company have been tracked by MarketBeat.com

Headlines

Teva Pharmaceutical Industries (NYSE TEVA) News Headlines

Source:
DateHeadline
Wells Fargo & Co Reiterates Sell Rating for Teva Pharmaceutical Industries (TEVA)Wells Fargo & Co Reiterates Sell Rating for Teva Pharmaceutical Industries (TEVA)
www.americanbankingnews.com - January 22 at 5:46 PM
Teva Pharmaceutical Industries (TEVA) "Hold" Rating Reiterated at Maxim GroupTeva Pharmaceutical Industries' (TEVA) "Hold" Rating Reiterated at Maxim Group
www.americanbankingnews.com - January 22 at 5:10 PM
Teva Late-stage Trial Of Asthma Treatment Fails To Meet Primary EndpointTeva Late-stage Trial Of Asthma Treatment Fails To Meet Primary Endpoint
www.nasdaq.com - January 22 at 3:43 PM
Teva shares decline on negative late-stage trial results for asthma therapyTeva shares decline on negative late-stage trial results for asthma therapy
finance.yahoo.com - January 22 at 3:43 PM
Why Teva Pharmaceutical Industries Ltd’s (ADR) Stock Is In The Red TodayWhy Teva Pharmaceutical Industries Ltd’s (ADR) Stock Is In The Red Today
finance.yahoo.com - January 22 at 3:43 PM
Tevas asthma treatment fails late-stage studiesTeva's asthma treatment fails late-stage studies
finance.yahoo.com - January 22 at 3:43 PM
Teva Announces Top-Line Results from Phase III Studies of Subcutaneously Administered Reslizumab in Patients with Severe Eosinophilic AsthmaTeva Announces Top-Line Results from Phase III Studies of Subcutaneously Administered Reslizumab in Patients with Severe Eosinophilic Asthma
finance.yahoo.com - January 22 at 8:16 AM
Generic-Drug Firms Fall as US Threatens to Sue for Damages - BloombergGeneric-Drug Firms Fall as US Threatens to Sue for Damages - Bloomberg
www.bloomberg.com - January 19 at 4:26 PM
Generic-Drug Firms Fall as U.S. Threatens to Sue for DamagesGeneric-Drug Firms Fall as U.S. Threatens to Sue for Damages
finance.yahoo.com - January 19 at 3:16 PM
Generic-Drug Makers Fall as Justice Department Threatens to SueGeneric-Drug Makers Fall as Justice Department Threatens to Sue
finance.yahoo.com - January 19 at 12:25 PM
How Hospitals Plan To Put Pressure On Generic-Drug MakersHow Hospitals Plan To Put Pressure On Generic-Drug Makers
finance.yahoo.com - January 18 at 3:17 PM
Teva cutting 200+ local jobs as part of broader restructuring planTeva cutting 200+ local jobs as part of broader restructuring plan
finance.yahoo.com - January 18 at 3:17 PM
BTIG Research Downgrades Teva Pharmaceutical Industries (TEVA) to NeutralBTIG Research Downgrades Teva Pharmaceutical Industries (TEVA) to Neutral
www.americanbankingnews.com - January 18 at 1:50 PM
Scoop Up Teva Pharmaceutical Industries Ltd (ADR) on Every DipScoop Up Teva Pharmaceutical Industries Ltd (ADR) on Every Dip
investorplace.com - January 18 at 1:13 PM
CTI BioPharma to Receive $10 Million Milestone Payment for TRISENOX®CTI BioPharma to Receive $10 Million Milestone Payment for TRISENOX®
www.prnewswire.com - January 18 at 2:25 AM
How This Biotech Stock Could Top Bigger Rivals In Preventing MigrainesHow This Biotech Stock Could Top Bigger Rivals In Preventing Migraines
finance.yahoo.com - January 16 at 3:15 PM
Teva Announces U.S. FDA Approval of TRISENOX® (arsenic ... - Business Wire (press release)Teva Announces U.S. FDA Approval of TRISENOX® (arsenic ... - Business Wire (press release)
www.businesswire.com - January 16 at 5:26 AM
How Teva Pharmaceutical Is Realigning Organizational StructureHow Teva Pharmaceutical Is Realigning Organizational Structure
finance.yahoo.com - January 15 at 10:37 AM
Teva Pharmaceutical Industries Ltd (TEVA) Short Interest UpdateTeva Pharmaceutical Industries Ltd (TEVA) Short Interest Update
www.americanbankingnews.com - January 15 at 2:28 AM
Teva Pharmaceutical Industries (TEVA) Stock Rating Lowered by VetrTeva Pharmaceutical Industries (TEVA) Stock Rating Lowered by Vetr
www.americanbankingnews.com - January 14 at 8:50 PM
Moodys slaps Teva with a downgrade - Teva Pharmaceutical ... - Seeking AlphaMoody's slaps Teva with a downgrade - Teva Pharmaceutical ... - Seeking Alpha
seekingalpha.com - January 13 at 5:34 AM
Teva Pharmaceutical Industries (TEVA) Stock Rating Lowered by Zacks Investment ResearchTeva Pharmaceutical Industries (TEVA) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - January 13 at 12:42 AM
The Key Challenges Teva Pharmaceutical Is FacingThe Key Challenges Teva Pharmaceutical Is Facing
finance.yahoo.com - January 12 at 4:03 PM
Teva Pharmaceutical Finance Netherlands II BV -- Moodys downgrades Teva to Ba2; outlook stableTeva Pharmaceutical Finance Netherlands II BV -- Moody's downgrades Teva to Ba2; outlook stable
finance.yahoo.com - January 12 at 4:03 PM
Teva to Lose 20–25 Sites, Cut 14,000 Workers in Next 2 YearsTeva to Lose 20–25 Sites, Cut 14,000 Workers in Next 2 Years
finance.yahoo.com - January 12 at 4:03 PM
General Electric among IQ 100 laggardsGeneral Electric among IQ 100 laggards
finance.yahoo.com - January 12 at 4:03 PM
A Look at Insys Therapeutics’ Financial PerformanceA Look at Insys Therapeutics’ Financial Performance
finance.yahoo.com - January 12 at 4:03 PM
Stock Exchange: Will Sentiment Turn Bearish Soon? - Seeking AlphaStock Exchange: Will Sentiment Turn Bearish Soon? - Seeking Alpha
seekingalpha.com - January 12 at 3:15 PM
Teva credit rating downgraded to junk status at MoodysTeva credit rating downgraded to junk status at Moody's
finance.yahoo.com - January 12 at 3:15 PM
The Laundry List of Reasons Behind Teva Pharmaceutical Industries 48% Tumble in 2017 - Motley FoolThe Laundry List of Reasons Behind Teva Pharmaceutical Industries' 48% Tumble in 2017 - Motley Fool
www.fool.com - January 12 at 5:25 AM
The Laundry List of Reasons Behind Teva Pharmaceutical Industries' 48% Tumble in 2017The Laundry List of Reasons Behind Teva Pharmaceutical Industries' 48% Tumble in 2017
finance.yahoo.com - January 11 at 11:13 AM
Teva Pharmaceutical Industries (TEVA) Downgraded by Goldman Sachs GroupTeva Pharmaceutical Industries (TEVA) Downgraded by Goldman Sachs Group
www.americanbankingnews.com - January 11 at 9:40 AM
Teva Pharmaceutical Industries Ltd (TEVA) Expected to Post Quarterly Sales of $5.28 BillionTeva Pharmaceutical Industries Ltd (TEVA) Expected to Post Quarterly Sales of $5.28 Billion
www.americanbankingnews.com - January 11 at 8:54 AM
Earnings Visibility Keep Teva Pharmaceutical Industries (TEVA) a Sell - Investorplace.comEarnings Visibility Keep Teva Pharmaceutical Industries (TEVA) a Sell - Investorplace.com
investorplace.com - January 11 at 5:21 AM
Teva Pharm directors cut their salaries in half: board member - Reuters - ReutersTeva Pharm directors cut their salaries in half: board member - Reuters - Reuters
www.reuters.com - January 11 at 5:21 AM
Teva: This Is Simply Too Great To Miss - Seeking AlphaTeva: This Is Simply Too Great To Miss - Seeking Alpha
seekingalpha.com - January 11 at 5:21 AM
Tevas Stock Price Surge Against Its Predictable WoesTeva's Stock Price Surge Against Its Predictable Woes
finance.yahoo.com - January 11 at 5:21 AM
Teva Stock Has Risen Significantly since November Lows: What’s Next?Teva Stock Has Risen Significantly since November Lows: What’s Next?
finance.yahoo.com - January 10 at 4:11 PM
Teva Pharm directors cut their salaries in half: board memberTeva Pharm directors cut their salaries in half: board member
finance.yahoo.com - January 10 at 3:16 PM
Mylan’s Valuation in January 2018Mylan’s Valuation in January 2018
finance.yahoo.com - January 10 at 3:16 PM
Mylan’s Quarterly Revenue TrendMylan’s Quarterly Revenue Trend
finance.yahoo.com - January 10 at 3:16 PM
Earnings Visibility Keep Teva Pharmaceutical Industries (TEVA) a SellEarnings Visibility Keep Teva Pharmaceutical Industries (TEVA) a Sell
investorplace.com - January 10 at 12:41 PM
Teva Pharm directors cut their salaries in half - board memberTeva Pharm directors cut their salaries in half - board member
finance.yahoo.com - January 10 at 10:54 AM
Mylan sees opportunity in rival Teva’s weaknessMylan sees opportunity in rival Teva’s weakness
finance.yahoo.com - January 10 at 5:34 AM
Teva Pharmaceutical Industries Ltd (TEVA) Given Average Recommendation of "Hold" by BrokeragesTeva Pharmaceutical Industries Ltd (TEVA) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - January 9 at 7:44 PM
Pharma leading the IQ 100Pharma leading the IQ 100
finance.yahoo.com - January 9 at 4:10 PM
Teva Tightens Belt, Now a BuyTeva Tightens Belt, Now a Buy
finance.yahoo.com - January 9 at 3:15 PM
Tevas Cost-Cutting Plan Nets A Mizuho UpgradeTeva's Cost-Cutting Plan Nets A Mizuho Upgrade
finance.yahoo.com - January 9 at 3:15 PM
Teva Announces Global License Agreement with Alder BioPharmaceuticals® in the Field of Anti-CGRP-Based Therapy - Business Wire (press release)Teva Announces Global License Agreement with Alder BioPharmaceuticals® in the Field of Anti-CGRP-Based Therapy - Business Wire (press release)
www.businesswire.com - January 8 at 11:19 AM
Mylan Dents Tevas Copaxone Market Share - Seeking AlphaMylan Dents Teva's Copaxone Market Share - Seeking Alpha
seekingalpha.com - January 8 at 9:30 AM

SEC Filings

Teva Pharmaceutical Industries (NYSE:TEVA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Teva Pharmaceutical Industries (NYSE:TEVA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Teva Pharmaceutical Industries (NYSE TEVA) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.